Full text
Earnings transcript
Read the complete earnings call transcript.
AVXL
Anavex Life Sciences Corp.
$2.99
-0.11
(-3.55%)
| Exchange: | NASDAQ |
| Market Cap: | 277.089M |
| Shares Outstanding: | 58.195M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Christopher U. Missling | |||||
| Full Time Employees: | 42 | |||||
| Address: |
| |||||
| Website: | https://www.anavex.com |
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer’s disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson’s disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company’s drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson’s, and Alzheimer’s diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| EBITDA | -46,541 | -43,002 | -46,377 |
| Operating Income | -55,763 | -52,877 | -51,408 |
| Net Income | -47,505 | -43,002 | -46,377 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 154,386 | 135,567 | 103,815 |
| Total Liabilities | 12,534 | 15,304 | 8,946 |
| Total Stockholders Equity | 141,852 | 120,263 | 94,869 |
| Total Debt | 0 | 0 | 0 |
| Cash and Cash Equivalents | 151,024 | 132,187 | 102,577 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -27,785 | -30,812 | -39,044 |
| Capital Expenditure | 0 | 0 | 0 |
| Free Cash Flow | -27,785 | -30,812 | -39,044 |
| Net Income | -47,505 | -43,002 | -46,377 |
| Net Change in Cash | 1,866 | -18,837 | -29,610 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 885,110 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 885,110 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 885,110 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 446,063.813 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 446,063.813 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 446,063.813 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 5.230 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 5.230 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 5.230 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 1 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Cash Position: Analysis of the Balance Sheet data indicates a strong level of cash and cash equivalents, providing AVXL with financial flexibility to fund research, development, and operational needs without immediate reliance on external financing.
- Innovative Pipeline: Insights from the Company Profile and Earnings Call Transcript highlight AVXL’s focus on novel therapeutic solutions within the biotechnology sector, potentially positioning the company as a leader in niche medical treatments.
- Positive Revenue Trends: Income Statement data shows consistent revenue growth over recent periods, reflecting successful product adoption or market penetration, which aligns with industry trends in the biotechnology sector as noted in Industry and Sector data.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about AVXL valuation
Is Anavex Life Sciences Corp. (AVXL) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Anavex Life Sciences Corp. (AVXL) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is AVXL a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether AVXL trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is AVXL’s P/E ratio?
You can see AVXL’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for AVXL?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is AVXL a good long-term investment?
Whether AVXL fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
AVXL
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-3.55
Trading Metrics:
| Open: | 3.03 | Previous Close: | 3.1 | |
| Day Low: | 2.95 | Day High: | 3.07 | |
| Year Low: | 2.61 | Year High: | 13.99 | |
| Price Avg 50: | 4.24 | Price Avg 200: | 6.98 | |
| Volume: | 1.159M | Average Volume: | 1.472M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeAVXL full analysis
Welcome to MARKETSNAP’s SWOT analysis for Anavex Life Sciences! If you’re a long-term investor looking to dig into a biotech player with some intriguing potential, you’ve come to the right place. Today, we’re breaking down Anavex Life Sciences, a company that’s not exactly a household name but is making waves in the biopharmaceutical space. Let’s unpack who they are, what’s been happening with them lately, and then dive into a detailed SWOT analysis to see if this stock deserves a…
